 However due to the extraordinarily high affinity of GTP/GDP for this site, it is unlikely that drug-like small molecule inhibitors could compete with GTP/GDP binding.Other than where GTP/GDP binds, there are no obvious high affinity binding sites for small molecules.One fairly frequent driver mutation is KRASG12C which is adjacent a shallow binding site.